Here's My Risk and Reward Parameters for Vir Biotechnology
Let's look over the charts and indicators.
Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak
The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.
Thrill Seekers Might Like 2 Downtrodden Stocks Insiders Are Buying
TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.
Market Participants Are Battling Omicron Pessimism
There are a number of issues to consider from a trading standpoint as we start the week.
Fingers Crossed for a Small-Cap Revenge Rally in 2022
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
How to Play AstraZeneca as Earnings Approach
Let's see how the charts are shaping up ahead of the numbers Friday.
GE Plans to Split Into 3: Here's MY Plan
Since GE CEO Larry Culp took the reins three years ago his plan has been nothing if not aggressive.
Options Play of the Week: Dipping Into Dynavax
Knee-jerk reactions to earnings results can create attractive opportunities.
Buying Moderna Now Could Be Akin to Trying to Catch a Falling Knife
Here's what traders can do.
Will Humana's Earnings Numbers Generate an Upside Breakout?
Let's take a look at the charts of this healthcare provider ahead of Wednesday's report.